1-9 of 9
William Wierda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff P. Sharman, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3918–3927.
https://doi.org/10.1158/1078-0432.CCR-19-2856
Published: 03 August 2020
View article titled, Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Open the PDF for Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study in another window
Includes: Supplementary data
Journal Articles

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Michael Hallek, William Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E. Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F. Seymour
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4371–4379.
https://doi.org/10.1158/1078-0432.CCR-17-3761
Published: 14 September 2018
View article titled, Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Open the PDF for Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1149–1155.
https://doi.org/10.1158/1078-0432.CCR-16-1431
Published: 28 February 2017
View article titled, Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Open the PDF for Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in another window
Includes: Supplementary data
Journal Articles

5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications

Andres Soriano, Hui Yang, Srdan Verstovsek, William Wierda, Charles Koller, Zeev Estrov, Souzanne Ouzounian, Hagop Kantarjian, Jean Pierre Issa, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B48.
Published: 15 August 2014
View article titled, 5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications
Journal Articles

Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease

Alma Zecevic, Deepa Sampath, Brett Ewald, Rong Chen, William Wierda, William Plunkett
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4731–4741.
https://doi.org/10.1158/1078-0432.CCR-10-2561
Published: 17 July 2011
View article titled, Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
Open the PDF for Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate

Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortes, Terry L. Smith, Mary Beth Rios, Jianqin Shan, Ying Yang, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia-Manero, Sima Jeha, William Wierda, Jean-Pierre J. Issa, Steven M. Kornblau, Michael Keating, Debra Resta, Renaud Capdeville, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2167–2176.
Published: 01 July 2002
View article titled, Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate
Open the PDF for Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate in another window